09/30/2025
After much anticipation, the Essilor Stellest myopia control glasses lenses have received FDA approval for use in the US. Coming soon to Focus 313 Eyecare!
France has had success with this technology since 2021 and China since 2020. We met with one of Essilor’s experts during our conference in Paris this weekend.
The Essilor Stellest lens received U.S. Food and Drug Administration authorization for marketing on September 25, 2025, making it the first spectacle lens authorized to slow the progression of myopia in children. The authorization was based on two years of clinical study data showing that the lenses slowed myopia progression by an average of 71% in children aged 6 to 12 compared to single vision lenses. This device uses Highly Aspherical Lenslet Target (HALT) technology, which creates peripheral light defocus to decrease myopia progression.